mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for GRIA2
Gene summary
Basic gene Info.Gene symbolGRIA2
Gene nameglutamate receptor, ionotropic, AMPA 2
CytomapUCSC genome browser: 4q32.1
Type of geneprotein-coding
DescriptionAMPA-selective glutamate receptor 2gluR-2gluR-Bglutamate receptor 2
Modification date20141222
dbXrefs MIM : 138247
Ensembl : ENSG00000120251
HPRD : 04726
Vega : OTTHUMG00000133836
ProteinUniProt: P42262
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_GRIA2
BioGPS: 2891
PathwayNCI Pathway Interaction Database: GRIA2
Pathway Commons: GRIA2
ContextiHOP: GRIA2
ligand binding site mutation search in PubMed: GRIA2
UCL Cancer Institute: GRIA2
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0035235ionotropic glutamate receptor signaling pathway20614889

Ligand binding site mutations for GRIA2
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for GRIA2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for GRIA2 from PDB

Differential gene expression and gene-gene network for GRIA2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of GRIA2 and the right PPI network was created from samples without mutations in the LBS of GRIA2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for GRIA2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0038220Status Epilepticus2Biomarker
umls:C0236736Cocaine-Related Disorders1Biomarker
umls:C0038587Substance Withdrawal Syndrome1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for GRIA2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
NutraceuticalDB00142L-Glutamic AcidSmall molecule
Approved|illicitDB00237ButabarbitalSmall molecule
Approved|illicitDB00241ButalbitalSmall molecule
Approved|illicitDB00306TalbutalSmall molecule
Approved|vet_approvedDB00312PentobarbitalSmall molecule
Approved|vet_approvedDB00418SecobarbitalSmall molecule
WithdrawnDB00463MetharbitalSmall molecule
Approved|vet_approvedDB00599ThiopentalSmall molecule
Approved|vet_approvedDB00794PrimidoneSmall molecule
ApprovedDB00849MethylphenobarbitalSmall molecule
ApprovedDB00898EthanolSmall molecule
ApprovedDB01174PhenobarbitalSmall molecule
ApprovedDB01346Quinidine barbiturateSmall molecule
Approved|illicitDB01351AmobarbitalSmall molecule
Approved|illicitDB01352AprobarbitalSmall molecule
Approved|illicitDB01353ButethalSmall molecule
ApprovedDB01354HeptabarbitalSmall molecule
ApprovedDB01355HexobarbitalSmall molecule
IllicitDB01483BarbitalSmall molecule
Experimental|illicitDB01496Barbituric acid derivativeSmall molecule
ExperimentalDB01664(S)-Des-Me-AmpaSmall molecule
ExperimentalDB02057(S)-AMPASmall molecule
ExperimentalDB023472-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)Propionic AcidSmall molecule
ExperimentalDB02818Iodo-WillardiineSmall molecule
ExperimentalDB02966Fluoro-WillardiineSmall molecule
ExperimentalDB02999QuisqualateSmall molecule
ExperimentalDB03240(S)-2-Amino-3-(1,3,5,7-Pentahydro-2,4-Dioxo-Cyclopenta[E]Pyrimidin-1-Yl) Proionic AcidSmall molecule
ExperimentalDB03319(S)-ATPASmall molecule
ExperimentalDB03759FG-9041Small molecule
ExperimentalDB04000Bromo-WillardiineSmall molecule
ExperimentalDB04129WillardiineSmall molecule
ExperimentalDB041522-Amino-3-(3-Hydroxy-7,8-Dihydro-6h-Cyclohepta[D]-4-Isoxazolyl)Propionic AcidSmall molecule
ExperimentalDB04599AniracetamSmall molecule
ExperimentalDB04798THIO-ATPASmall molecule
InvestigationalDB04982TalampanelSmall molecule
Illicit|investigationalDB05047CX717Small molecule
ExperimentalDB07455N,N'-[biphenyl-4,4'-diyldi(2R)propane-2,1-diyl]dimethanesulfonamideSmall molecule
ExperimentalDB075982,3,6A,7,8,9-HEXAHYDRO-11H-[1,4]DIOXINO[2,3-G]PYRROLO[2,1-B][1,3]BENZOXAZIN-11-ONESmall molecule
ExperimentalDB08303(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxideSmall molecule
ExperimentalDB08304(3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxideSmall molecule
ExperimentalDB08305(3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxideSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of GRIA2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of GRIA2
Multiple alignments for P42262 in multiple species
LBSAA sequence# speciesSpecies
E423VTTILESPYVM3Homo sapiens, Mus musculus, Rattus norvegicus
G752NLDSKGYGIAT3Homo sapiens, Mus musculus, Rattus norvegicus
I502IAPLTITLVRE3Homo sapiens, Mus musculus, Rattus norvegicus
K514VIDFSKPFMSL3Homo sapiens, Mus musculus, Rattus norvegicus
K751GNLDSKGYGIA3Homo sapiens, Mus musculus, Rattus norvegicus
L500IAIAPLTITLV3Homo sapiens, Mus musculus, Rattus norvegicus
L772VNLAVLKLNEQ3Homo sapiens, Mus musculus, Rattus norvegicus
M517FSKPFMSLGIS3Homo sapiens, Mus musculus, Rattus norvegicus
N775AVLKLNEQGLL3Homo sapiens, Mus musculus, Rattus norvegicus
P499DIAIAPLTITL3Homo sapiens, Mus musculus, Rattus norvegicus
P515IDFSKPFMSLG3Homo sapiens, Mus musculus, Rattus norvegicus
R506TITLVREEVID3Homo sapiens, Mus musculus, Rattus norvegicus
S518SKPFMSLGISI3Homo sapiens, Mus musculus, Rattus norvegicus
S750GGNLDSKGYGI3Homo sapiens, Mus musculus, Rattus norvegicus
T501AIAPLTITLVR3Homo sapiens, Mus musculus, Rattus norvegicus
T707VFVRTTAEGVA3Homo sapiens, Mus musculus, Rattus norvegicus
V771AVNLAVLKLNE3Homo sapiens, Mus musculus, Rattus norvegicus
Y426ILESPYVMMKK3Homo sapiens, Mus musculus, Rattus norvegicus
Y471VGDGKYGARDA3Homo sapiens, Mus musculus, Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas